Supercharging cancer treatment

For over 15 years, scientists at Ulster University have been developing stimulus responsive therapeutic systems, primarily to address the adverse effects associated with the use of cancer chemotherapeutic drugs. During those studies, the benefits of providing a transient, in situ source of molecular oxygen during therapy became abundantly clear and it was out of this that StimOxyGen was born.